Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Trial Profile

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Coronary disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DECLARE; DECLARE-TIMI58
  • Sponsors AstraZeneca
  • Most Recent Events

    • 15 Sep 2017 Baseline characteristics of the DECLARE-TIMI 58 trial population, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 13 Jun 2017 Trial design and baseline characteristics presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 08 Jun 2017 According to an AstraZeneca media release, trial design and baseline characteristics will be presented at the American Diabetes Associations (ADA) 77th Scientific Sessions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top